Atara biotherapeutics, inc. (ATRA)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Dec'13
Assets
Current assets:
Cash and cash equivalents

70,203

74,317

94,431

59,159

56,168

60,698

66,028

103,203

90,495

79,223

60,493

64,237

62,430

47,968

46,013

26,356

22,056

23,746

54,466

26,190

71,329

21,897

25,703

51,615

Short-term investments

144,428

184,792

188,491

130,976

181,377

248,933

298,515

313,812

316,826

86,873

139,728

152,659

168,216

207,714

232,134

268,201

284,347

296,736

279,799

128,841

95,367

82,219

25,996

-

Restricted cash - short-term

194

194

194

194

194

194

194

194

194

194

194

194

194

194

194

194

194

194

-

-

-

-

-

-

Prepaid expenses and other current assets

14,392

13,689

10,302

10,810

13,091

11,664

8,239

7,861

6,099

5,900

5,802

5,402

4,478

4,677

3,889

4,132

5,144

3,921

5,970

5,603

2,995

1,910

323

193

Total current assets

229,217

272,992

293,418

201,139

250,830

321,489

372,976

425,070

413,614

172,190

206,217

222,492

235,318

260,553

282,230

298,883

311,741

324,597

340,235

160,634

169,691

106,026

52,022

51,808

Property and equipment, net

54,442

54,176

55,697

57,090

58,119

68,576

68,279

66,075

58,194

44,129

22,176

20,287

4,400

3,259

2,085

1,830

1,148

270

46

42

47

48

14

8

Operating lease assets

13,691

14,007

14,204

14,396

14,041

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash - long-term

1,200

1,200

1,200

1,200

1,200

1,200

1,200

1,200

1,200

1,200

1,200

1,200

1,200

0

-

-

-

-

-

-

-

-

-

-

Other assets

997

567

266

319

536

574

485

362

100

260

100

176

820

102

102

101

89

108

98

426

79

48

2,084

12

Total assets

299,547

342,942

364,785

274,144

324,726

391,839

442,940

492,707

473,108

217,779

229,693

244,155

241,738

263,914

284,417

300,814

312,978

324,975

340,379

161,102

169,817

106,122

54,120

51,828

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

8,079

7,963

5,155

6,420

6,168

3,719

6,193

6,545

6,098

14,711

5,539

5,243

2,204

2,778

4,463

3,235

1,896

1,445

1,853

1,703

794

440

569

606

Accrued compensation

9,676

14,706

12,897

7,822

7,459

10,636

9,072

5,276

4,312

5,664

5,319

3,262

2,609

3,745

3,156

2,135

1,337

2,624

1,562

924

522

1,225

500

331

Accrued research and development expenses

7,827

8,341

6,172

5,139

6,194

19,210

3,803

6,661

6,336

4,006

3,810

2,071

2,106

2,408

5,109

3,799

4,430

5,112

-

-

-

824

-

-

Other current liabilities

5,938

5,733

6,482

6,422

5,354

6,414

7,932

8,752

4,303

3,265

1,848

905

886

744

960

837

1,197

528

3,034

4,516

2,197

235

1,280

432

Income tax payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1

1

-

63

155

License fee payable to Memorial Sloan Kettering Cancer Center ("MSK")

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,500

-

-

-

-

Total current liabilities

31,520

36,743

30,706

25,803

25,175

39,979

27,000

27,234

21,049

27,646

16,516

11,481

7,805

9,675

13,688

10,006

8,860

9,709

6,450

11,644

3,514

2,724

2,412

1,524

Operating lease liabilities - long-term

13,809

14,136

14,532

14,919

14,437

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

1,396

1,282

1,105

1,143

1,180

13,003

12,886

12,974

12,875

12,269

7,221

11,530

799

503

527

563

284

166

181

203

209

216

165

230

Total liabilities

46,725

52,161

46,343

41,865

40,792

52,982

39,886

40,208

33,924

39,915

23,737

23,011

8,604

10,178

14,215

10,569

9,144

9,875

6,631

11,847

3,723

2,940

2,577

1,754

Commitments and contingencies (Note 7)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

74,572

61,091

Stockholders’ equity:
Preferred stock$0.0001 par value, 20,000,000 shares authorized; none issued and outstanding as of September 30, 2015 and December 31, 2014

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

Common stock—$0.0001 par value, 500,000 shares authorized as of March 31, 2020 and December 31, 2019; 58,940 and 56,806 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

6

6

5

5

5

5

5

5

4

3

3

3

3

3

3

3

3

3

3

2

2

2

-

1

Additional paid-in capital

1,144,082

1,108,516

1,057,669

899,671

877,133

866,541

850,835

841,975

777,797

474,662

467,378

451,496

436,096

431,075

429,088

423,600

418,451

413,725

410,556

214,313

216,159

144,169

7,344

2,200

Notes receivable from stockholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

335

Accumulated other comprehensive income

204

220

233

173

38

-340

-449

-505

-524

-151

-88

-114

-152

-183

35

193

51

-518

51

-66

-18

-100

-11

-

Accumulated deficit

-891,500

-817,961

-739,500

-667,600

-593,242

-527,349

-447,337

-388,976

-338,093

-296,650

-261,337

-230,241

-202,813

-177,159

-158,924

-133,551

-114,671

-98,110

-76,862

-64,994

-50,049

-40,889

-30,362

-12,883

Total stockholders’ equity

252,822

290,781

318,442

232,279

283,934

338,857

403,054

452,499

439,184

177,864

205,956

221,144

233,134

253,736

270,202

290,245

303,834

315,100

333,748

149,255

166,094

103,182

-23,029

-11,017

Total liabilities and stockholders’ equity

299,547

342,942

364,785

274,144

324,726

391,839

442,940

492,707

473,108

217,779

229,693

244,155

241,738

263,914

284,417

300,814

312,978

324,975

340,379

161,102

169,817

106,122

54,120

51,828